Recombinant viruses of the paramyxoviridae family with heterologous envelope glycoproteins
AssigneeThe UAB Research Foundation
InventorsAntonius G. P. Oomens, Gail W. Wertz, Alexander George Megaw
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe UAB Research Foundation
InventorsAntonius G. P. Oomens, Gail W. Wertz, Alexander George Megaw
Estimating the term…
The invention provides recombinant viruses comprising heterologous envelope proteins capable of mediating entry of the recombinant viruses into host cells. In one embodiment, a recombinant virus of the invention is a member of the Paramyx-ovirzdae family (e.g., a respiratory syncytial virus), and the heterologous envelope protein includes the ectodomain of a baculovirus envelope protein (e.g., the GP64 protein). In some cases, the heterologous envelope protein is provided in addition to homologous envelope proteins) which may or may not be functional. The heterologous protein can provide the recombinant virus with enhanced stability (e.g., at 4° C., 22° C., or 37° C.), and allows production of high-titer virus stocks. The heterologous protein can also impart temperature sensitivity to the replication of the recombinant virus. In addition, the recombinant virus can be designed to be infectious but incapable of spreading between host cells by providing the heterologous protein by complementation in trans. These features attenuate the disease-causing potential of the recombinant virus, therefore increasing its safety of use as vaccines.
A recombinant, live, attenuated virus of the Paramyxoviridae family comprising a baculovirus GP64 envelope glycoprotein capable of mediating entry of said recombinant virus into a mammalian cell;
An enveloped recombinant, live, attenuated virus of the Paramyxoviridae family comprising a heterologous envelope protein baculovirus GP64, wherein said envelope protein is capable of mediating entry of the recombinant virus into a mammalian cell, wherein the recombinant virus has been stored for at least 3.5 days, wherein infectivity of the recombinant virus at the end of said at least 3.5 days is at least 60% of that at the beginning of said at least 3.5 days, and wherein the average infectivity of a wild-type virus of the same species as the recombinant virus, when stored the same as the recombinant virus for said at least 3.5 days, is reduced by more than 40%.
A recombinant, live, attenuated respiratory syncytial virus (RSV) comprising a baculovirus GP64 envelope glycoprotein capable of mediating entry of said recombinant RSV into a mammalian cell;
Dependencies are inferred from the claim text.